127 related articles for article (PubMed ID: 35101866)
1. Somatic Mutations Enriched in Cis-Regulatory Elements Affect Genes Involved in Embryonic Development and Immune System Response in Neuroblastoma.
Lasorsa VA; Montella A; Cantalupo S; Tirelli M; de Torres C; Aveic S; Tonini GP; Iolascon A; Capasso M
Cancer Res; 2022 Apr; 82(7):1193-1207. PubMed ID: 35101866
[TBL] [Abstract][Full Text] [Related]
2. Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma.
Capasso M; Lasorsa VA; Cimmino F; Avitabile M; Cantalupo S; Montella A; De Angelis B; Morini M; de Torres C; Castellano A; Locatelli F; Iolascon A
Cancer Res; 2020 Feb; 80(3):382-393. PubMed ID: 31784426
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
4. Mutations in Noncoding
El Ghamrasni S; Quevedo R; Hawley J; Mazrooei P; Hanna Y; Cirlan I; Zhu H; Bruce JP; Oldfield LE; Yang SYC; Guilhamon P; Reimand J; Cescon DW; Done SJ; Lupien M; Pugh TJ
Mol Cancer Res; 2022 Jan; 20(1):102-113. PubMed ID: 34556523
[TBL] [Abstract][Full Text] [Related]
5. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
[TBL] [Abstract][Full Text] [Related]
6. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
7. Cis-regulatory somatic mutations and gene-expression alteration in B-cell lymphomas.
Mathelier A; Lefebvre C; Zhang AW; Arenillas DJ; Ding J; Wasserman WW; Shah SP
Genome Biol; 2015 Apr; 16(1):84. PubMed ID: 25903198
[TBL] [Abstract][Full Text] [Related]
8. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
9. Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer.
Corona RI; Seo JH; Lin X; Hazelett DJ; Reddy J; Fonseca MAS; Abassi F; Lin YG; Mhawech-Fauceglia PY; Shah SP; Huntsman DG; Gusev A; Karlan BY; Berman BP; Freedman ML; Gayther SA; Lawrenson K
Nat Commun; 2020 Apr; 11(1):2020. PubMed ID: 32332753
[TBL] [Abstract][Full Text] [Related]
10. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
Murphy DM; Buckley PG; Bryan K; Das S; Alcock L; Foley NH; Prenter S; Bray I; Watters KM; Higgins D; Stallings RL
PLoS One; 2009 Dec; 4(12):e8154. PubMed ID: 19997598
[TBL] [Abstract][Full Text] [Related]
11. Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer.
Lowdon RF; Wang T
PLoS One; 2017; 12(3):e0174032. PubMed ID: 28333948
[TBL] [Abstract][Full Text] [Related]
12. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
13. Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
Murphy DM; Buckley PG; Das S; Watters KM; Bryan K; Stallings RL
PLoS One; 2011; 6(6):e21436. PubMed ID: 21731748
[TBL] [Abstract][Full Text] [Related]
14. Functional annotation of noncoding mutations in cancer.
Umer HM; Smolinska K; Komorowski J; Wadelius C
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282050
[TBL] [Abstract][Full Text] [Related]
15. Alterations in transcriptional networks in cancer: the role of noncoding somatic driver mutations.
Doane AS; Elemento O
Curr Opin Genet Dev; 2022 Aug; 75():101919. PubMed ID: 35609422
[TBL] [Abstract][Full Text] [Related]
16. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
[TBL] [Abstract][Full Text] [Related]
17. Leveraging Tissue-Specific Enhancer-Target Gene Regulatory Networks Identifies Enhancer Somatic Mutations That Functionally Impact Lung Cancer.
Hariprakash JM; Salviato E; La Mastra F; Sebestyén E; Tagliaferri I; Silva RS; Lucini F; Farina L; Cinquanta M; Rancati I; Riboni M; Minardi SP; Roz L; Gorini F; Lanzuolo C; Casola S; Ferrari F
Cancer Res; 2024 Jan; 84(1):133-153. PubMed ID: 37855660
[TBL] [Abstract][Full Text] [Related]
18. A Significant Regulatory Mutation Burden at a High-Affinity Position of the CTCF Motif in Gastrointestinal Cancers.
Umer HM; Cavalli M; Dabrowski MJ; Diamanti K; Kruczyk M; Pan G; Komorowski J; Wadelius C
Hum Mutat; 2016 Sep; 37(9):904-13. PubMed ID: 27174533
[TBL] [Abstract][Full Text] [Related]
19. The search for cis-regulatory driver mutations in cancer genomes.
Poulos RC; Sloane MA; Hesson LB; Wong JW
Oncotarget; 2015 Oct; 6(32):32509-25. PubMed ID: 26356674
[TBL] [Abstract][Full Text] [Related]
20. Suppression of RIZ in biologically unfavourable neuroblastomas.
Geli J; Kiss N; Kogner P; Larsson C
Int J Oncol; 2010 Nov; 37(5):1323-30. PubMed ID: 20878080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
